98%
921
2 minutes
20
Type 2 diabetes mellitus (T2DM)-related cognitive decline is associated with neuroimaging changes. However, only a few studies have focused on early functional alteration in T2DM prior to mild cognitive impairment (MCI). This study aimed to investigate the early changes of global connectivity patterns in T2DM by using a resting-state functional magnetic resonance imaging (rs-fMRI) technique. Thirty-four T2DM subjects and 38 age-, sex-, and education-matched healthy controls (HCs) underwent rs-fMRI in a 3T MRI scanner. Degree centrality (DC) was used to identify the functional hubs of the whole brain in T2DM without MCI. Then the functional connectivity (FC) between hubs and the rest of the brain was assessed by using the hub-based approach. Compared with HCs, T2DM subjects showed increased DC in the right cerebellum lobules III-V. Hub-based FC analysis found that the right cerebellum lobules III-V of T2DM subjects had increased FC with the right cerebellum crus II and lobule VI, the right temporal inferior/middle gyrus, and the right hippocampus. Increased DC in the right cerebellum regions III-V, as well as increased FC within cerebellar regions and ipsilateral cerebrocerebellar regions, may indicate an important pathophysiological mechanism for compensation in T2DM without MCI.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533640 | PMC |
http://dx.doi.org/10.3389/fneur.2020.01016 | DOI Listing |
Cureus
August 2025
Department of Medicine, Bangladesh Institute of Health Sciences (BIHS) General Hospital, Dhaka, BGD.
Objective: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder frequently associated with obesity, leading to increased risks of cardiovascular and renal complications. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a promising therapeutic agent for improving glycemic control and promoting weight reduction. However, evaluating its safety and efficacy in obese T2DM patients remains essential, particularly in real-world clinical settings.
View Article and Find Full Text PDFDiab Vasc Dis Res
September 2025
Mary and Steve Wen Cardiovascular Division, School of Medicine, University of California, Irvine, CA, USA.
BackgroundThe SUSTAIN-6 trial showed the cardiovascular disease (CVD) benefits of semaglutide among patients with type 2 diabetes mellitus (T2DM). We estimated the US population eligibility and preventable CVD events from semaglutide.MethodsUS adults with T2DM were selected from the National Health and Nutrition Examination Survey 2011-2020 based on SUSTAIN-6 eligibility criteria.
View Article and Find Full Text PDFJ Clin Lipidol
August 2025
ANZAC Research institute, Concord Repatriation General Hospital and University of Sydney, Sydney, NSW, Australia (Drs Kockx, Wang, and Kritharides); Department of Cardiology, Concord Repatriation General Hospital, Sydney Local Health District and University of Sydney, Sydney, NSW, Australia (Dr Krit
Background: Indigenous Australians have an increased risk of type 2 diabetes mellitus (T2DM) and premature cardiovascular disease. Subpopulations of high-density lipoprotein (HDL) have been associated with increased cardiovascular risk, but HDL composition, size, or function have not been studied in Indigenous Australians.
Methods: The study consisted of 86 non-Indigenous participants, 43 of whom had T2DM, and 75 Indigenous participants, 36 of whom had T2DM.
Cureus
August 2025
Department of Family Medicine, King Abdullah bin Abdulaziz University Hospital, Riyadh, SAU.
Background: Traveling has become an important part of Saudi people's lives. Those diagnosed with type 2 diabetes mellitus (T2DM) encounter various challenges during travel that can adversely affect glycemic control. Studies have highlighted critical gaps in the knowledge, attitudes, and practices (KAP) of family medicine physicians in Saudi Arabia regarding pre-travel counseling for patients with type 2 diabetes.
View Article and Find Full Text PDFWorld J Methodol
December 2025
Department of Endocrinology, Sir H.N. Reliance Foundation Hospital and Research Centre, Mumbai 400004, India.
Background: Data on the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM) during Ramadan fasting is limited. No meta-analysis has summarized the safety and effectiveness of GLP-1RAs in these situations.
Aim: To evaluate the safety and efficacy of GLP-1RA in patients with T2DM fasting during Ramadan.